FDA Advisory Panel Backs First Multi-Cancer Early Detection Blood Test

The Food and Drug Administration now has a formal recommendation to approve the first blood test capable of screening for more than 50 types of cancer, setting up a final regulatory decision in the coming months. On September 23, 2026, the FDA’s Molecular and Clinical Genetics Devices Panel voted to back Grail’s Galleri multi-cancer early detection test for adults aged 50 and older. The agency, which is not bound by the advisory committee's vote but typically follows its guidance, holds the ultimate authority on whether the test will enter the broader commercial market.[1][2]

The Galleri test operates by analyzing cell-free DNA shed into the bloodstream by both healthy and tumor cells. It searches for cancer-specific methylation patterns—chemical modifications on the DNA that act as a signature for malignancies. If a cancer signal is detected, the test uses next-generation sequencing to predict the tissue of origin, directing physicians on where to look during subsequent diagnostic workups like MRI or PET scans.[2][4]

The 10-member advisory panel cast three separate tallies to evaluate the device's premarket approval application. The committee voted 10-0 that the test is safe, but split 6-4 in support of its effectiveness. On the final question of whether the test's overall benefits outweigh its risks, the panel voted 7-2, with one abstention, providing the narrow endorsement required to move the application forward.[1][5]

That divided vote reflects a fundamental tension in the clinical data between the test's high specificity and its mixed sensitivity. According to trial data presented to the committee, the test maintains a 99.85% specificity rate, meaning false positives occur in fewer than one in a hundred patients. However, critics on the panel noted that the test misses approximately 85% of stage 1 cancers, raising questions about its utility in catching the earliest, most treatable tumors.[2]

Proponents of the technology emphasize its ability to detect aggressive malignancies that currently lack any guideline-recommended screening, such as pancreatic, esophageal, and ovarian cancers. In patients with cancers lacking standard screening options, the test demonstrated an 80.0% sensitivity for liver and intrahepatic bile duct cancers, and a 75.0% sensitivity for ovarian or fallopian tube cancers.[2][5]

Grail CEO Josh Ofman stated that the panel's vote "reinforces the strength of Galleri's clinical evidence" and helps find cancers "when they may be easier and less costly to treat." The company has consistently positioned the blood draw as a complement to, rather than a replacement for, standard preventative care.[2][4]

The unanimous safety vote masked underlying concerns among panelists about behavioral risks, particularly how patients and doctors might misinterpret a negative result. Victor van Berkel, a committee member, noted that his primary concern was "false reassurance leading to either ignoring symptoms or other screening guidelines." He emphasized that the blood test is designed strictly as an addition to established regimens like mammograms and colonoscopies.[1][2]

The FDA is expected to issue its final ruling on the premarket approval application before the end of the year. If authorized, the Galleri assay would become the first FDA-approved multi-cancer early detection test on the market, shifting the landscape of preventative oncology while requiring a massive educational effort for primary care providers who will be tasked with interpreting the results.[3][4]